Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mirasol-treated red blood cells
- Development stage
- Unknown
- Lead developer
- Terumo BCT
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Mirasol-treated red blood cells are a blood product processed using the Mirasol Pathogen Reduction Technology (PRT) system, developed by Terumo BCT. This technology utilizes riboflavin (vitamin B2), a naturally occurring photosensitizer, in combination with ultraviolet (UV) light to inactivate a broad range of pathogens, including viruses, bacteria, and parasites, as well as residual white blood cells in donated blood. The mechanism involves riboflavin intercalating into the nucleic acids of pathogens and leukocytes; upon exposure to UV light, the riboflavin mediates a photochemical reaction that causes irreversible damage to DNA and RNA, thereby preventing replication. This process is designed to enhance the safety of chronic blood transfusions in patients with conditions such as transfusion-dependent thalassemia by reducing the risk of transfusion-transmitted infections and transfusion-associated graft-versus-host disease (TA-GVHD) without the need for gamma irradiation.
- Brand names
- Mirasol
- Other names
- Mirasol-treated RBCsMirasol PRT-treated red blood cellsMirasol-treated whole blood-derived red blood cells
Beyond the preview
Go deeper on Mirasol-treated red blood cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirasol-treated red blood cells.